2173 related articles for article (PubMed ID: 8261423)
1. Expression of calcyclin in human melanocytic lesions.
Weterman MA; van Muijen GN; Bloemers HP; Ruiter DJ
Cancer Res; 1993 Dec; 53(24):6061-6. PubMed ID: 8261423
[TBL] [Abstract][Full Text] [Related]
2. Expression of calcyclin in human melanoma cell lines correlates with metastatic behavior in nude mice.
Weterman MA; Stoopen GM; van Muijen GN; Kuznicki J; Ruiter DJ; Bloemers HP
Cancer Res; 1992 Mar; 52(5):1291-6. PubMed ID: 1737392
[TBL] [Abstract][Full Text] [Related]
3. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
de Vries TJ; Verheijen JH; de Bart AC; Weidle UH; Ruiter DJ; van Muijen GN
Cancer Res; 1996 Mar; 56(6):1432-9. PubMed ID: 8640836
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
7. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor.
Pötgens AJ; van Altena MC; Lubsen NH; Ruiter DJ; de Waal RM
Am J Pathol; 1996 Apr; 148(4):1203-17. PubMed ID: 8644861
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
[TBL] [Abstract][Full Text] [Related]
11. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
12. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
13. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
14. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
15. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases.
Schietroma C; Cianfarani F; Lacal PM; Odorisio T; Orecchia A; Kanitakis J; D'Atri S; Failla CM; Zambruno G
Cancer; 2003 Aug; 98(4):789-97. PubMed ID: 12910524
[TBL] [Abstract][Full Text] [Related]
17. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44 variant isoforms in malignant melanoma.
Seiter S; Schadendorf D; Herrmann K; Schneider M; Rösel M; Arch R; Tilgen W; Zöller M
Clin Cancer Res; 1996 Mar; 2(3):447-56. PubMed ID: 9816190
[TBL] [Abstract][Full Text] [Related]
19. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 expression in melanocytic lesions of the skin.
Ramirez JA; Guitart J; Rao MS; Diaz LK
Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
